Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 7, 2000, Pages 869-878

  Thumshirn, M ^a   Coulie, B ^a   Camilleri, M ^a   Zinsmeister, A R ^a   Burton, D D ^a   Van Dyke, C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BALLOON DILATATION; CLINICAL TRIAL; COLD STRESS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; INTESTINE TRANSIT TIME; IRRITABLE COLON; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM; SCINTIGRAPHY;

ADULT; AGED; CARBOLINES; COLONIC DISEASES, FUNCTIONAL; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL TRANSIT; HUMANS; MALE; MIDDLE AGED; PSYCHOMOTOR PERFORMANCE; RECTUM; SEROTONIN ANTAGONISTS;

EID: 0033938748     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00786.x     Document Type: Article

References (50)

1. 1 Drossman DA, Camilleri M, Whitehead WE. Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology 1997; 112: 2120-37.
2. 2 Camilleri M, Choi M-G. Review article: Irritable bowel syndrome. Aliment Pharm Ther 1997; 11: 3-15.
3. 3 Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology 1991; 100: 998-1005.
4. 4 Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987; 92: 1282-4.
5. 5 Evans PR, Bennett EJ, Bak YT, Tennant CC, Kellow JE. Jejunal sensorimotor dysfunction in irritable bowel syndrome: clinical and psychological features. Gastroenterology 1996; 110: 393-404.
6. 6 Whitehead WE, Holtkotter B, Enck P, et al. Tolerance of rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990; 98: 1187-92.
7. 7 Munakata J, Naliboff B, Harraf F, et al. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997; 112: 55-63.
8. 8 Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable bowel syndrome. Gut 1973; 14: 123-32.
9. 9 Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40-52.
10. 10 Vassallo M, Camilleri M, Phillips SF, Brown ML, Chapman NJ, Thomforde GM. Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology 1992; 102: 102-8.
11. 11 Cann PA, Read NW, Brown C, Hobson N, Holdsworth CD. Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns. Gut 1983; 24: 405-11.
12. 12 Moss HE, Sanger GJ. The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induced by duodenal distention. Br J Pharm 1990; 100: 497-501.
13. 13 Scott CM, Grundy D, Boissonade F, Bountra C. Alosetron inhibits the colorectal distention-evoked depressor response and spinal c-fos expression in the anesthetized rat. Gastroenterology 1997; 112: A822(Abstract).
14. 14 Talley NJ. 5-Hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment Pharmacol Ther 1990; 25: 273-89.
15. 15 Prior A, Read NW. Reduction of rectal sensitivity and postprandial motility by granisetron, a 5HT3 receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharm Ther 1993; 7: 175-80.
16. 16 Zighelboim J, Talley NJ, Phillips SF, Harmsen WS, Zinsmeister AR. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distention and serotonin type 3 antagonism. Dig Dis Sci 1995; 40: 819-27.
17. 17 Maxton DG, Morris J, Whorwell PJ. Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? Aliment Pharm Ther 1996; 10: 595-9.
18. 18 Steadman CJ, Talley NJ, Phillips SF, et al. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc 1992; 67: 732-8.
19. 19 Goldberg PA, Kamm MA, Setti-Carraro P, van der Sijp JRM, Roth C. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5HT3 antagonism (ondansetron). Digestion 1996; 57: 748-83.
20. 20 Gore S, Gilmore IT, Haigh CG, Brownless SM, Stockdale H, Morris AI. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydrxytryptamine receptor (type 3) antagonist. Aliment Pharm Ther 1990; 4: 139-44.
21. 21 Talley NJ, Phillips SF, Haddad A, et al. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990; 35: 477-80.
22. 22 von der Ohe MR, Hanson RB, Camilleri M. Serotonergic mediation of postprandial colonic tonic and phasic responses in humans. Gut 1994; 35: 536-41.
23. 3-receptor antagonist. Aliment Pharmacol Ther 1999; 13: 1149-59.
24. 24 Forster JM, Houghton LA, Whorwell PJ. Alosetron slows colonic transit in patients with irritable bowel syndrome. Gastroenterology 1997; 112: A732(Abstract).
25. 25 Delvaux M, Louvel D, Lagier E, Scherrer B, Abitbol J-L, Frexinos J. The agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999; 116: 38-45.
26. 26 Anon. Alosetron. Clinical Investigator's Brochure. Glaxo Wellcome Pharmaceuticals Research and Development 1995.
27. 27 Thompson WG, Creed F, Drossman DA, Heaton KW, Mazzacca G. Functional bowel disorders and functional abdominal pain. Gastroenterol Int 1992; 5: 75-91.
28. 28 Manning AP, Thompson WD, Heaton KW, Morris AF. Towards a positive diagnosis of the irritable bowel syndrome. Br Med J 1978; 2: 653-4.
29. 29 Camilleri M, Colemont LJ, Phillips SF, et al. Human gastric emptying and colonic filling of solids characterized by a new method. Am J Physiol 1989; 257: G284-90.
30. 30 Proano M, Camilleri M, Phillips SF, et al. Transit of solids through the human colon: regional quantification in the unprepared bowel. Am J Physiol 1990; 258: G856-62.
31. 31 Camilleri M, Zinsmeister AR, Greydanus MP, Brown ML, Proano M. Towards a less costly but accurate test of gastric emptying and small bowel transit. Dig Dis Sci 1991; 36: 606-15.
32. 32 Camilleri M, Zinsmeister AR. Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders. Gastroenterology 1992; 103: 36-42.
33. 33 Camilleri M, Brown ML, Malagelada JR. Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology 1986; 91: 94-9.
34. 34 Burton DD, Camilleri M, Mullan BP, Forstrom LA, Hung JC. Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets. J Nucl Med 1997; 38: 1807-10.
35. 35 Azpiroz F, Malagelada JR. Physiological variations in canine gastric tone measured by an electronic barostat. Am J Physiol 1985; 248: G229-37.
36. 36 Moreels TG, Foley M, Phillips SF. In vitro comparison of internal compliances of three barostats. Dig Dis Sci 1996; 41: A15(Abstract).
37. 37 Malcolm A, Phillips SF, Camilleri M, Hanson RB. Pharmacological modulation of rectal tone alters perception of distention in humans. Am J Gastroenterol 1997; 92: 2073-9.
38. 38 Bharucha AE, Camilleri M, Ford MJ, O'Connor MK, Hanson RB, Thomforde GM. Hyperventilation alters colonic motor and sensory function; effects and mechanisms in humans. Gastroenterology 1996; 111: 368-77.
39. 39 Bharucha AE, Camilleri M, Zinsmeister AR, Hanson RB. Adrenergic modulation of human colonic motor and sensory function. Am J Physiol 1997; 273: G1135-40.
40. 40 Ford MJ, Camilleri M, Zinsmeister AR, Hanson RB. Psychosensory modulation of colonic sensation in the human transverse and sigmoid colon. Gastroenterology 1995; 109: 1772-80.
41. 41 Ford MJ, Camilleri M, Joyner MJ, Hanson RB. Autonomic control of colonic tone and the cold pressor test. Gut 1996; 39: 125-9.
42. 42 Akkervall S, Fasth S, Nordgren S, et al. Manovolumetry: a new method for investigation of anorectal function. Gut 1988; 29: 614-23.
43. 43 Bell AM, Pemberton JH, Hanson RB, et al. Variations in muscle tone of the human rectum: recordings with an electromechanical barostat. Am J Physiol 1991; 260: G17-25.
44. 44 Hammer HF, Phillips SF, Camilleri M, Hanson RB. Rectal tone, distensibility, and perception: reproducibility and response to different distentions. Am J Physiol 1998; 274: G584-90.
45. 45 Saslow SB, Scolapio JS, Camilleri M, et al. Medium term effects of a new 5HT3 antagonist, alosetron, in patients with carcinoid diarrhea. Gut 1998; 42: 628-34.
46. 47 Zerbib F, Bruley des Varannes S, Oriola RC, McDonald J, Isal JP, Galmiche JP. Alosetron does not affect the visceral perception of gastric distension in healthy subjects. Aliment Pharmacol Ther 1994; 8: 403-7.
47. 48 Bearcroft CP, Andre EA, Farthing MJ. In vivo effects of the 5-HT3 antagonist alosetron on basal and cholera toxin-induced secretion in the human jejunum: a segmental perfusion study. Aliment Pharmacol Ther 1997; 11: 1109-14.
48. 49 Greenshaw AJ, Silverstone PH. The non-antiemetic uses of serotonin 5HT3 receptor antagonists. Drugs 1997; 53: 20-39.
49. 50 Miura M, Lawson C, Clary EM, Mangel AW, Pappas TN. Central modulation of rectal distension-induced blood pressure changes by alosetron, a 5-HT3 receptor antagonist. Dig Dis Sci 1999; 44: 20-4.
50. 51 Nishizawa S, Benkelfat C, Young SN, et al. Differences between males and females in rates of serotonin synthesis in human brain. Proc Natl Acad Sci USA 1997; 94: 5308-13.